Boryung
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Boryung is a South Korean pharmaceutical company that develops and supplies prescription and over-the-counter medicines to patients and healthcare providers.
Its products are distributed through hospitals, clinics, and pharmacies in Korea. Listed on KOSPI, Korea's main stock exchange, the company conducts its own research and development activities alongside its commercial pharmaceutical business.
Summary is AI-generated and may contain errors · figures from DART filings
Boryung in five facts
What does Boryung do?
Boryung is a South Korean pharmaceutical company that develops and supplies prescription and over-the-counter medicines to patients and healthcare providers.
Where is Boryung listed and in which sector?
Boryung (Korean name: 보령) trades under KRX code 003850 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Boryung?
Its market capitalisation was US$546.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Boryung's latest annual revenue and operating profit?
For fiscal year 2025, Boryung reported revenue of US$767.9M, operating profit of US$49.1M and net income of US$48.5M, per its annual report on DART (data retrieved from DART on 2026-09-06). Revenue was up 0.0% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-06
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Proxy solicitation reference documentOct 13
- Notice of general shareholders' meetingOct 13
- Supply contract signedSupply contract · Sep 22
- Report on large shareholdings (5% rule) (standard)Sep 21
- [Attachment amended] Material event report (spin-off)M&A · Sep 16
- Shareholder register closure / record date setSep 15
- Resolution to convene a general shareholders' meetingSep 15
- [Amended] Treasury share disposal: results reportTreasury Shares · Sep 15
- [Amended] Material event report (treasury share disposal)
Boryung updated a disclosed plan to sell treasury shares worth US$2.54M, about 0.5% of its market value.
Treasury Shares · Sep 15 - Material event report (spin-off)M&A · Sep 15
- Treasury share acquisition: results reportTreasury Shares · Sep 11
- Operating results (consolidated) (preliminary) (fair disclosure)
Boryung filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$197M (+11.2% year on year), operating profit of US$16.7M (−6.2% year on year) and net income of US$16.9M (+171.4% year on year).
Earnings · Aug 6 - Material event report (treasury share acquisition)
Boryung disclosed a plan to buy back its own shares worth US$13.2M, about 2.8% of its market value.
Treasury Shares · Jun 12 - Operating results (consolidated) (preliminary) (fair disclosure)
Boryung filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$173M (+6.15% year on year), operating profit of US$13.7M (+84.65% year on year) and net income of US$28.1M (+11773.4% year on year).
Earnings · Apr 30 - Cash/in-kind dividend decision
Boryung declared a cash dividend of US$0.11 per share.
Dividend · Feb 23 - [Amended] Operating results (consolidated) (preliminary) (fair disclosure)
Boryung updated its previously filed provisional (unaudited) consolidated results for Q4 2025: revenue of US$170M (−4.5% year on year), an operating loss of US$450K (from a profit a year earlier) and net income of US$14.6M (+59.37% year on year).
Earnings · Feb 13 · 2 versions